Such is the case of Venetoclax (ABT-199) [23] and Navitoclax (ABT-263) [24], a small molecule inhibitor directed against BCL-2, clinically approved for use in ALL, CLL, and AML [23]. Here, BCL2 is linked to acute myeloid leukemia.